Fierce Pharma

SEPTEMBER 4, 2024

Over the last decade, three blockbuster drugs—Biogen’s Spinraza, Roche’s Evrysdi and Novartis’ gene therapy Zolgensma—have transformed the treatment landscape for spinal muscular atrophy (SMA). | Biogen revealed that a portion of its phase 2/3 DEVOTE study met its primary endpoint, as a higher dose of Spinraza improved the motor function of treatment-naive infants with spinal muscular atrophy.

299

299

MedCity News

SEPTEMBER 4, 2024

In this episode, we’re joined by Carolee Lee, CEO and founder of Women’s Health Access Matters (WHAM), and Ash Shehata, KPMG U.S. sector leader for healthcare. The two discuss WHAM and KPMG’s new partnership that aims to advance women’s health research and investment. The post MedCity FemFwd: Inside WHAM & KPMG’s Women’s Health Partnership appeared first on MedCity News.

Healthcare 129

Healthcare Healthcare 129

Fierce Pharma

SEPTEMBER 4, 2024

Several months after its parent company unveiled new labs and office space to unite cell and gene therapy research on the West Coast, Astellas Gene Therapies is turning out the lights at a Californ | Several months after its parent company unveiled new labs and office space to unite cell and gene therapy research on the West Coast, Astellas Gene Therapies is turning out the lights at a California production plant.

299

299

MedCity News

SEPTEMBER 4, 2024

Eli Lilly now offers vials of obesity medication Zepbound directly to self-pay patients at a nearly 50% discount off the drug’s list price. But more than offering patients a lower-cost alternative, this move represents a strategic stance against certain pharmaceutical industry players. The post With Direct-to-Patient Zepbound, Eli Lilly Takes a Stand Against Compounders and PBMs appeared first on MedCity News.

Patients 128

Patients Medical Pharmaceutical Biopharma 128

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Fierce Pharma

SEPTEMBER 4, 2024

With a shortage of ADHD drugs persisting, the DEA has raised production limits on Takeda’s Vyvanse and its generic versions by 24%, the agency said.

264

264

MedCity News

SEPTEMBER 4, 2024

Health systems’ financial results suggest the start of sustained recovery, but persistent challenges remain, including rising expenses and less-than-ideal reimbursement rates from payers. The post How Have Hospitals Fared Financially So Far in 2024? appeared first on MedCity News.

119

119

MedCity News

SEPTEMBER 4, 2024

Healthcare organizations should work proactively with experts in the relevant domains to recognize and mitigate potential cybersecurity risks. Here’s what to do to mitigate risk. The post Recognizing and Mitigating Cybersecurity Risks: Strategies for Healthcare Organizations appeared first on MedCity News.

Healthcare 115

Healthcare Healthcare Physicians 115

pharmaphorum

SEPTEMBER 4, 2024

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).The full results of the FENopta open-label extension study are due to be reported in full at the ECTRIMS congress in Copenhagen later this month, but top-line findings include that 99% of patients treated with fenebrutinib were free of T1 gadolinium-enhancing lesions, markers of active inflammation, at 48 w

Patients 105

Patients 105

MedCity News

SEPTEMBER 4, 2024

Wearable technology seems to offer great potential for early detection and management of agitation experienced by people with communication-impaired neurological disorders, allowing caregivers to provide personalized interventions that could significantly improve patients’ lives. The post Digital Biomarkers in Agitation Detection: Enhancing Care for Communication-Impaired Neurological Disorders appeared first on MedCity News.

Management 110

Management Patients Healthcare Healthcare 110

Pharmaceutical Technology

SEPTEMBER 4, 2024

Actimed says S-oxprenolol shares a similar pharmacology to its lead product S-pindolol, which is being studied in cachexia.

Pharmacology 105

Pharmacology FDA Leads 105

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

Pharmaceutical Commerce

SEPTEMBER 4, 2024

The latest news for pharma industry insiders.

Pharma 104

Pharma 104

Pharmaceutical Technology

SEPTEMBER 4, 2024

Merck has gained EC approval for KEYTRUDA plus Padcev for adults with unresectable or metastatic urothelial carcinoma.

104

104

pharmaphorum

SEPTEMBER 4, 2024

Regeneron signs up for access to a study run by Koneksa exploring the use of digital biomarkers to track patients with Parkinson's.

Patients 99

Patients 99

Pharmaceutical Technology

SEPTEMBER 4, 2024

Pfizer Ignite will support Acepodia in developing its pipeline cancer therapeutic candidates.

98

98

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

ALULA

SEPTEMBER 4, 2024

"There isn't a playbook for every challenge," says Tom Frosina, Operations Leader at TD Bank. Tom knows that leadership isn't about following a script. Instead, effective leaders must be able to adapt, innovate, and empower their teams to succeed.

98

98

Clarivate

SEPTEMBER 4, 2024

The Web of Science Research Assistant, a generative AI-powered tool built with and for researchers, is now available to the global research community. After extensive collaboration and testing with the research community that began in December 2023, we are pleased to announce the global launch of the Web of Science Research Assistant. The research assistant combines the power of generative artificial intelligence (AI), the Web of Science knowledge graph and an all-new chat interface to provide r

Government 98

Government Consulting Training Networking 98

Pharmaceutical Technology

SEPTEMBER 4, 2024

By integrating the best practices from decentralized trials, CROs can optimize efficiencies and streamline site-based operations, ensuring that site-centric trials remain effective and innovative.

98

98

pharmaphorum

SEPTEMBER 4, 2024

Swiss startup Haya Therapeutics has formed a $1bn partnership with Eli Lilly to look for new therapies for obesity in non-coding DNA

97

97

Advertisement

Pharmacy Times

SEPTEMBER 4, 2024

In a promising development in multiple sclerosis research, tolebrutinib delayed the onset of disability progression in patients with nrSPMS.

Patients 59

Patients 59

pharmaphorum

SEPTEMBER 4, 2024

Novartis' Fabhalta is first oral monotherapy for paroxysmal nocturnal haemoglobinuria cleared by NICE for NHS use.

81

81

PharmaVoice

SEPTEMBER 4, 2024

More companies are investing in protein degraders, which leverage a unique approach to harnessing the immune system in cancer, neurological diseases and more.

59

59

Pharmaceutical Technology

SEPTEMBER 4, 2024

The US Food and Drug Administration (FDA) has granted fast track designation to Innovent Biologics' IBI363 for treating melanoma.

Food and Drug Administration 59

Food and Drug Administration FDA Food 59

Advertisement

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

Sales

Pharmacy Times

SEPTEMBER 4, 2024

The authors stress that health care providers should explain false positive results to their patients, reassure them that results may be negative, and stress the significance of continued screenings.

Patients 52

Patients 52

PharmaTech

SEPTEMBER 4, 2024

Webinar Date/Time: Tue, Sep 24, 2024 11:00 AM EDT

52

52

Pharmacy Times

SEPTEMBER 4, 2024

New insights into heart failure risks in Native American communities are highlighting the need to address social determinants of health.

52

52

Evolve Your Success

SEPTEMBER 4, 2024

Dr. Dan McMahon, a general surgeon with a remarkable blend of military service and expertise in surgical technology, joins us to unravel the future of medical sales. COVID-19 has driven a significant transformation in the industry, pushing digital interactions to the forefront. Dr. McMahon provides an in-depth look at how platforms like LinkedIn and podcasts are not just trendy but essential tools for medical sales reps and physicians striving to stay ahead.

Medical sales 52

Medical sales Medical sales reps Consulting Sales 52

Advertisement

Distribution

PharmaTech

SEPTEMBER 4, 2024

Among the design features of the machine is software-based tracking that is meant to ensure that products that are temperature-sensitive do not exceed their time limit in the solution.

52

52

PharmExec

SEPTEMBER 4, 2024

Results from the FINE-HEART pooled analysis of three Phase III clinical trials highlighted the potential of finerenone in treating high-risk cardiovascular patients.

Patients 52

Patients 52

Pharmaceutical Technology

SEPTEMBER 4, 2024

ProKidney is prioritising one of two clinical studies evaluating rilparencel, to bring the cell therapy to the US market quicker.

Marketing 52

Marketing 52

PharmExec

SEPTEMBER 4, 2024

Data from the Phase II/III DEVOTE study demonstrated that Spinraza showed significant motor function improvements at six months in infants with spinal muscular atrophy.

52

52

Advertisement

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

Sales